The
investment in account receivable consists of the following at March 31, 2026 and December 31, 2025:
Schedule of receivables with imputed interest
| | |
March 31,
2026 | | |
December 31,
2025 | |
| Face value* | |
$ | 287,200 | | |
$ | 287,200 | |
| Impairment | |
| (250,208 | ) | |
| (250,208 | ) |
| Total | |
| 36,992 | | |
| 36,992 | |
| Unamortized discount | |
| (36,992 | ) | |
| (36,992 | ) |
| Net balance | |
| - | | |
| - | |
| Long term portion | |
$ | - | | |
$ | - | |
| * | Coincident
with the June 11, 2024 impairment, accounts receivable of $2,300 were reclassed and concurrently impaired. Prior to the full impairment,
the Company reduced the face value of its investment in account receivable by an additional $100 per month for five receivable payment
installments. |
|